Essential thrombocytosis overview

Jump to navigation Jump to search

Essential thrombocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Causes

Differentiating Essential thrombocytosis from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Essential thrombocytosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Essential thrombocytosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Essential thrombocytosis overview

CDC on Essential thrombocytosis overview

Essential thrombocytosis overview in the news

Blogs on Essential thrombocytosis overview

Directions to Hospitals Treating Essential thrombocytosis

Risk calculators and risk factors for Essential thrombocytosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Essential thrombocytosis (ET, also known as essential thrombocythemia) is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow in the absence of an alternative cause. In some cases this disorder may be progressive, and rarely may evolve into acute myeloid leukemia or myelofibrosis. It is one of four myeloproliferative disorders.

References


Template:WikiDoc Sources